Floatz logo

Mevrometostat

Metastatic Castration Sensitive Prostate Cancer (mCSPC)

PfizerSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

251 Active assets in the Metastatic Castration Sensitive Prostate Cancer (mCSPC) cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Mevrometostat is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →